Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Ibuprofen vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever reduction,Juvenile idiopathic arthritis,Patent ductus arteriosus closure (off-label),Pericarditis (off-label),Gout (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via CYP2C9 (major) and CYP2C8 (minor); also undergoes glucuronidation. Metabolites are inactive.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
99% bound primarily to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.1-0.2 L/kg; low Vd consistent with high protein binding and limited tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 80-100% (rapidly and completely absorbed).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-60 m L/min: no adjustment needed; GFR 15-29 m L/min: 200 mg every 12 hours; GFR <15 m L/min: avoid use.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest effective dose (200 mg every 8-12 hours); maximum 400 mg/day due to increased risk of GI bleeding and renal impairment.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Cardiovascular thrombotic events,Gastrointestinal ulceration, bleeding, perforation,Hypertension,Heart failure exacerbation,Renal toxicity (including acute renal failure, interstitial nephritis),Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic effects (e.g., anemia, prolonged bleeding time),Hepatic impairment,Asthmatic reactions in aspirin-sensitive patients
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in coronary artery bypass graft surgery,Active gastrointestinal bleeding, ulceration, or perforation,Advanced renal disease,Pregnancy (third trimester),Severe heart failure (NYHA class IV),Cerebrovascular bleeding
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Alcohol: increases GI irritation and bleeding risk. Grapefruit juice: no significant interaction. High-fat meals may delay absorption but do not reduce overall bioavailability.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential oligohydramnios and fetal renal impairment. Third trimester: Contraindicated; risk of premature ductus arteriosus closure, persistent pulmonary hypertension, oligohydramnios, and fetal nephrotoxicity.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Ibuprofen is compatible with breastfeeding. M/P ratio approximately 0.6–1.1. Transfer into breast milk is low; relative infant dose <1% maternal weight-adjusted dose. Preferred NSAID during lactation due to short half-life and low infant exposure.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Physiological changes in pregnancy (increased volume of distribution, renal clearance) may reduce serum concentrations. However, no specific dose adjustment is routinely recommended. Use lowest effective dose for shortest duration. Avoid in third trimester.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Ibuprofen has a ceiling effect for analgesia; exceeding 400 mg per dose provides minimal additional pain relief but increases GI and cardiovascular risks. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. In asthma patients, note that NSAIDs can trigger bronchospasm in approximately 10% of aspirin-sensitive individuals. For acute pain, a single dose of 400-800 mg is effective; for chronic use, use the lowest effective dose for the shortest duration. Ibuprofen is highly protein-bound and may displace warfarin, increasing INR; monitor closely.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day without a doctor's approval; maximum OTC dose is 400 mg every 4-6 hours.,Avoid alcohol while taking ibuprofen to reduce the risk of stomach bleeding.,Stop taking and contact your doctor if you experience signs of stomach bleeding: black or bloody stools, vomiting blood, or severe abdominal pain.,Ibuprofen can increase risk of heart attack or stroke, especially with long-term use or high doses; discuss your cardiovascular risk with your doctor.,Do not take ibuprofen if you are pregnant (especially in the third trimester) unless directed by your doctor, as it can harm the unborn baby.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Ibuprofen vs ACTIQ, answered by our medical review team.
Ibuprofen is a NSAID that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Ibuprofen and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Ibuprofen is: 200-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Ibuprofen and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Ibuprofen is classified as Category D/X. First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential o. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.